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1024 The Journal of Thoracic and CardObjectives: Freedom from anticoagulation is the principal advantage of bioprosthe-
sis; however, the American Heart Association/American College of Cardiology and
the American College of Chest Physicians guidelines recommend early anticoagu-
lation with heparin, followed by warfarin for 3 months after bioprosthetic aortic
valve replacement. We examined neurologic events within 90 days of bioprosthetic
aortic valve replacement at our institution.
Methods: Between 1993 and 2000, 1151 patients underwent bioprosthetic aortic
valve replacement with (641) or without (510) associated coronary artery bypass. By
surgeon preference, 624 had early postoperative anticoagulation (AC) and 527 did
not (AC–). In the AC– group, 410 patients (78%) received antiplatelet therapy.
Groups were similar with respect to gender (female, 36% AC vs 40% AC–, P 
.21), hypertension (64% AC vs 61%, P  .27), and prior stroke (7.6% AC vs
8.5% AC–, P  .54). The AC group was slightly younger than the AC– group
(median, 76 years vs 78 years, P  .006).
Results: Operative mortality was 4.1% with 43 (3.7%) cerebrovascular events
within 90 days. Excluding 18 deficits apparent upon emergence from anesthesia, we
found that postoperative cerebrovascular accident occurred in 2.4% of AC and
1.9% AC– patients. By multivariable analysis, the only predictor of operative
mortality was hypertension (P  .0001). Postoperative cerebrovascular accident
was unrelated to warfarin use (P  .32). The incidence of mediastinal bleeding
requiring reexploration was similar (5.0% vs 7.4%), as were other bleeding com-
plications in the first 90 days (1.1% vs 0.8%). No variables were predictive of
bleeding by multivariate analysis.
Conclusions: Although these data do not address the role of antiplatelet agents, early
anticoagulation with warfarin after bioprosthetic aortic valve replacement did not
appear to protect against neurologic events.
The principal advantage of biological aortic valve prostheses over mechanicalprostheses is freedom from anticoagulation. Accordingly, bioprostheses areused commonly in elderly patients and in others in whom the risks associated
with anticoagulation are believed to be high. Long-term results with tissue valves
have shown a low incidence of complications1; however, early thromboembolic
events, particularly with bioprostheses in the mitral position, have been reported.2
Accordingly, the guidelines for valve replacement developed by the American Heart
Association and American College of Cardiology (AHA/ACC)3 and by the Amer-
ican College of Chest Physicians (ACCP)4 recommend early anticoagulation with
heparin, followed by warfarin for the first 3 months after bioprosthetic aortic valve
replacement (AVR). Similar recommendations have been made by the European
Society of Cardiology as well.5
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CDEarly anticoagulant therapy is intended to provide pro-
tection from thromboembolic events while the cloth sewing
ring is endothelialized. The recommended duration of war-
farin therapy may be viewed as brief; unfortunately, the
risks of anticoagulant-related hemorrhage are highest during
the first 3 months of therapy.6 The recommended strategy,
therefore, subjects those patients we are most reluctant to
anticoagulate to a significant risk of complications.
Despite the published guidelines, opinion and practice











Prior CVA 92 (8.0%)
Cerebrovascular disease 169 (14.7%)
Renal insufficiency (Cr  2) 57 (5.2%)
Diabetes 224 (19.5%)
COPD 166 (14.4%)
Prior MI 192 (16.7%)
NYHA class
Class I 49 (4.3%)
Class II 176 (15.3%)
Class III 728 (63.5%)
Class IV 194 (16.9%)
Endocarditis 16 (1.4%)
Atrial fibrillation at surgery 68 (5.9%)
History of atrial fibrillation (not




Aortic stenois and regurgitation
Ejection fraction
Mean  SD 56.4  15.2
Median 60
Ejection fraction  30% 74 (6.6%)
Hypercholesterolemia 682 (59.9%)
CAD 788 (68.5%)
Left main disease  50% 129 (11.7%)
Previous CABG 120 (10.4%)
Preop anticoagulant 267 (23.2%)
Preop aspirin 640 (55.6%)
Preop nonaspirin antiplatelet 33 (3.3%)
Left ventricular hypertrophy 328 (28.5%)
Anticoag , Receiving heparin and warfarin; Anticoag , not receiving he
pulmonary disease; MI, myocardial infarction; NYHA, New York Heart Ass
artery bypass graft; preop, preoperative.bioprosthetic valve replacement remains divided. Indeed,
The Journal of Thoracicthe aforementioned guidelines themselves are somewhat
inconsistent, with the AHA/ACC panel judging early
anticoagulation a class I indication, whereas the authors
of the ACCP guidelines grade the evidence for this to be
only 2C. Furthermore, the British Society of Hematolo-
gists recommends only antiplatelet therapy after biolog-
ical AVR.6
The practice in our own institution reflects this diversity
of opinion. After publication of a Mayo Clinic study advo-




(n  527) P value
75.9 7.6 76.7 8.6 .006
76 78
.209
399 (63.9%) 318 (60.3%)
225 (36.1%) 209 (39.7%)
399 (64.3%) 322 (61.1%) .271
47 (7.6%) 45 (8.5%) .541
91 (14.6%) 78 (14.9%) .896
26 (4.3%) 31 (6.4%) .118
130 (20.9%) 94 (17.8%) .196
95 (15.2%) 71 (13.5%) .399
108 (17.4%) 84 (16.0%) .520
.443
26 (4.2%) 23 (4.4%)
100 (16.1%) 76 (14.5%)
395 (63.5%) 333 (63.4%)
101 (16.2%) 93 (17.7%)
12 (1.9%) 4 (0.8%) .093
41 (6.6%) 27 (5.1%) .300
58 (9.3%) 38 (7.2%) .203
120 (19.2%) 91 (17.3%) .391
36 (5.8%) 27 (5.1%) .631
467 (74.8%) 407 (77.2%) .345
56.7  15.1 56.1 15.3 .602
60 60
41 (6.8%) 33 (6.4%) .789
378 (61.4%) 304 (58.1%) .267
419 (67.3%) 369 (70.0%) .315
69 (11.6%) 60 (11.9%) .859
66 (10.6%) 54 (10.3%) .855
154 (24.7%) 113 (21.4%) .195
336 (53.9%) 304 (57.7%) .192
23 (4.2%) 10 (2.3%) .095
170 (27.2%) 158 (30.0%) .305
and warfarin; CVA, cerebrovascular accident; COPD; chronic obstructive
on; AFib, atrial fibrillation; CAD, coronary artery disease; CABG, coronaryparin
ociatifollowed by warfarin therapy for 3 months,7 some surgeons
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This diversity in practice pattern, therefore, provides 2
groups of patients for retrospective analysis of the impact of
warfarin therapy on cerebral ischemic events during the first
90 days after bioprosthetic AVR.
Methods
After obtaining appropriate institutional review board approval, a
retrospective analysis of patients undergoing bioprosthetic AVR
between January 1993 and January 2000 was undertaken. Cases
were identified by a search of our computerized clinical database.
Patients undergoing associated coronary artery bypass were in-
cluded; those undergoing other concomitant procedures were not.
TABLE 2. Operative characteristics
All patients
(n  1151)
Concomitant CABG 641 (55.7%)
Crossclamp time
Mean  SD 64.0 23.7
Median 59.5
Bypass time










Preop insertion 5 (0.4%)
Intraop insertion 36 (3.1%)
VAD 1 (0.1%)
Anticoag , Receiving heparin and warfarin; Anticoag , not receiving he
intraop, intraoperative; IABP, intra-aortic balloon pump; VAD, ventricular
TABLE 3. Operative results
All patients
(n  1151)
Mortality (operative) 47 (4.1%)
Reexploration for bleeding 70 (6.1%)
MI 6 (0.5%)
Postop IABP 7 (0.6%)




Mean  SD 10.3 9.1
Median 8
Anticoag , Receiving heparin and warfarin; Anticoag , not receiving
intra-aortic balloon pump; preop, preoperative; LOS, length of stay.
1026 The Journal of Thoracic and Cardiovascular Surgery ● MaFollow-up was obtained between September 6, 2002, and
December 1, 2003. Hospital charts of all patients were reviewed
and abstracted for in-hospital events and any subsequent events
noted in the hospital record. In-hospital follow-up was 100%
complete. Ninety-day follow-up was not routinely collected pro-
spectively. Accordingly, postal questionnaires were mailed to pa-
tients alive at the time of follow-up and telephone calls made to
those not responding to the postal questionnaire. Information re-
garding anticoagulant use and thromboembolic or other neurologic
events out to 90 days was obtained through one of these means in
87% of patients.
All suspected cerebral ischemic events were reviewed and




(n  527) P value
8 (54.2%) 303 (57.5%) .257
.5 23.3 57.6 22.6 .001
67 53
.6 37.3 86.6 41.8 .001
101 79
.002
8 (39.7%) 164 (31.1%)
6 (60.3%) 363 (68.9%)
.793
2 (96.5%) 505 (95.8%)
9 (3.1%) 18 (3.4%)
3 (0.5%) 4 (0.8%)
4
1 (0.2%) 5 (0.8%) .185
4 (2.2%) 22 (4.2%) .061
0 (0.0%) 1 (0.2%) .458





(n  527) P value
6 (1.0%) 41 (7.8%) .001
31 (5.0%) 39 (7.4%) .085
3 (0.5%) 3 (0.6%) 1.000
1 (0.2%) 6 (1.1%) .052
0 (0.0%) 5 (1.0%) .019
9.6 5.5 11.2 12.1 .741
8 8











Sundt et al Surgery for Acquired Cardiovascular Disease
A
CDgroup. Postoperative delirium was not scored as stroke. Patients in
whom a deficit developed after they had awakened intact from
anesthesia were scored as having a postoperative event, while
those awakening with a deficit or those never regaining conscious-
ness postoperatively were scored as having intraoperative events.
Because of the realities of clinical practice, a strict definition of
thromboembolic stroke was frequently not possible from the hos-
pital record. In some cases, the consulting neurologist speculated
with regard to etiology, distinguishing embolic from hypertensive
or hypotensive infarction, but this was not uniform. Accordingly,
in the interest of an inclusive data set, either a clinical diagnosis of
stroke or evidence of cerebral infarction by computed tomographic
or magnetic resonance imaging was accepted as evidence of a
cerebral ischemic event. There was only 1 reversible cerebral
ischemic event identified within the 90-day interval. No peripheral
embolic events were identified.
Members of the Division of Cardiovascular Surgery, Mayo
Clinic Rochester, performed all operations. Mild hypothermic or
normothermic cardiopulmonary bypass was routine. Cardioplegic
arrest was achieved by blood or crystalloid cardioplegia, per the
individual surgeon’s preference. The prosthesis type inserted was
also at the discretion of the operating surgeon.
Postoperative management was at the discretion of the individ-
ual surgeon. Some members of the division routinely anticoagu-
lated patients, beginning intravenous heparin within 24 hours of
surgery and converting to warfarin before discharge from the
hospital. Others were treated with aspirin only or no anticoagulant
at all. Of patients not receiving warfarin, 78% received antiplatelet
therapy. Patients experiencing atrial fibrillation were routinely
administered anticoagulants before discharge. Patients were allo-
cated to AC (early postoperative anticoagulation with heparin
and warfarin) or AC– (no anticoagulation ) groups on the basis of
medications at the time of discharge from the hospital or at the
time of in-hospital stroke, if such occurred.
Statistical Analysis
Categorical factors were compared between groups by using
Fisher exact tests. For groups with severity classifications, such as
aortic valve regurgitation, the P value is based on an absent versus
present response. Logistic regression models were used to con-
struct a multivariate model to predict operative mortality. A step-








Intraop 18 9 9
30 days 19 11 8
30-90 days 6 5 1




Anticoag , Receiving heparin and warfarin; Anticoag , not receiving
heparin and warfarin; CVA, cerebrovascular accident; intraop,
intraoperative.wise selection technique was used to identify factors for the final
The Journal of Thoracicmultivariate model. Potential risk factors for long-term endpoints
such as stroke outside the intraoperative period were evaluated by
the Cox proportional hazards models. Age was adjusted for 10-
year intervals.
Results
During the study interval, slightly more than half of the
patients undergoing AVR received anticoagulation with
heparin and warfarin (AC group). As shown in Table 1,
the median age of the AC group was slightly less than that
of the AC– group, although this difference is not likely to be
clinically significant. There was no significant difference in
gender distribution or in the incidence of hypertension,
diabetes, prior cerebrovascular accident, or renal insuffi-
ciency. Patients in both groups were of similar New York
Heart Association class and had similar ejection fractions. A
slightly greater number of patients with endocarditis re-
ceived aggressive anticoagulation, although this indication
for surgical intervention represented only a very small por-
tion of the study group. Similar percentages of patients were
in atrial fibrillation at the time of surgery.
Operative characteristics of both study groups were also
quite similar (Table 2). Bypass times as well as crossclamp
times were slightly longer in the AC group, although these
differences were not likely of clinical significance. There
was no difference in distribution of porcine verses bovine
prostheses. A slightly greater number of patients in the AC–
group received intra-aortic balloon pumps intraoperatively;
however, this event was uncommon, and the difference did
not reach statistical significance.
The operative mortality rate appeared higher in the AC
group (Table 3). Interpretation of this observation is com-
plicated by the retrospective nature of this study, as indi-
viduals not surviving the operative interval long enough to
receive anticoagulation are necessarily classified as AC–.
TABLE 5. Analysis for operative mortality
Variable Odds ratio 95% CI P value
Univariable
Male 0.74 0.41, 1.33 .32
Diag of CAD 1.53 0.77, 3.04 .23
Hypertension 5.22 2.05, 13.30 .0005
Prior CVA 2.09 0.91, 4.82 .08
Prior CV intervention 1.74 0.95, 3.21 .07
Prior CABG 1.82 0.83, 3.99 .14
CAB done 0.90 0.50, 1.62 .72
Age 1.14 0.77, 1.70 .51
Multivariable
Hypertension 0.19 0.08, 0.49 .0001
CI, Confidence interval; diag, diagnosis; CAD, coronary artery disease;
CVA, cerebrovascular event; CV, cardiovascular; CABG, coronary artery
bypass grafting; CAB, coronary artery bypass.The higher incidence in the AC– group of new onset renal
and Cardiovascular Surgery ● Volume 129, Number 5 1027
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CDfailure, a marker for multisystem dysfunction, supports this
interpretation. Importantly, there was no difference between
groups with respect to reoperation for bleeding.
Postoperative neurologic events occurred in 43 patients
(Table 4). Of these, 18 events were judged likely intraop-
erative events as noted above. They were excluded from
further analysis, as the focus of this study is the impact of
postoperative management on postoperative outcome.
Among the remaining events, similar numbers occurred in
the AC  and AC– groups. At the time of the event, 17
patients were in sinus rhythm. Of these 17 patients, 10 were
receiving aggressive anticoagulation. A similar distribution
prevailed among the 8 patients in atrial fibrillation at the
time of stroke, with 5 anticoagulated and 3 not. Unfortu-
nately information regarding the management of the left
atrial appendage at surgery is incomplete, although it is not
routine in this institution to ligate this structure during
AVR.
Univariate analysis of risk factors for operative mortality
yielded only hypertension as a predictor (Table 5). No risk
factors for postoperative stroke within 90 days, including
history of atrial fibrillation, atrial fibrillation at he time of
surgery, ejection fraction, or age, were apparent (Table 6)
This may be due in part to the small number of events
recorded. Postoperative warfarin did not appear protective.




ratio 95% CI P value
Male 0.65 0.29, 1.44 .29
Diag of CAD 1.86 0.69, 5.00 .22
Hypertension 1.54 0.64, 3.71 .34
Prior CVA 2.24 0.75, 6.68 .15
Prior CV intervention 0.95 0.37, 2.39 .91
Prior CABG — — .96
CAB done 1.20 0.53, 2.69 .66
Warfarin 1.51 0.66, 3.46 .32
Age 1.48 0.81, 2.71 .20
History of Afib (not in Afib
at time of surgery)
0.96 0.22, 4.11 .95
Afib at surgery — — .97
EF  30 — — .97
ASA 1.02 0.45, 2.32 .97
CI, Confidence interval; diag, diagnosis; CAD, coronary artery disease;
CVA, cerebrovascular event; CV, cardiovascular; CABG, coronary artery
bypass grafting; CAB, coronary artery bypass; Afib, atrial fibrillation; EF,
ejection fraction; ASA, aspirin. *A stepwise multivariable logistic model
was done with all of the above variables. Age has been adjusted for
10-year intervals. No variables were significant in the multivariable model.
Note: The dashes indicate that the hazard ratio and 95% CI were not
calculated, because there were no patients with a stroke who had any of
these events.Similarly, there was no apparent benefit to aspirin, although
1028 The Journal of Thoracic and Cardiovascular Surgery ● Mathe majority of patients were on this medication. As shown
in Table 7, no risk factors achieved significance for post-
operative bleeding.
Discussion
The results of our study demonstrate no apparent benefit to
early anticoagulation in the first 90 days after bioprosthetic
AVR. While there was no apparent increase in bleeding
complications, there was also no reduction in stroke. On the
basis of the data presented here, we no longer routinely
administer heparin and warfarin to patients after biopros-
thetic AVR, although we continue to administer aspirin to
most patients. The ever-advancing age of patients undergo-
ing valve replacement and the emphasis on earlier discharge
argue in favor of such a selective approach to anticoagula-
tion after bioprosthetic AVR. We agree that factors influ-
encing the risk of thromboembolism, such as age, tobacco
abuse, hypertension, diabetes, hyperlipidemia, atrial fibril-
lation, ventricular function, left atrial size (50 mm on
echocardiography), previous thromboembolism, and hyper-
coagulable states, encourage anticoagulation as suggested
by Goldsmith.6 Indeed, an argument may be made for the
use of mechanical prostheses among patients with strong
indications for anticoagulation postoperatively.8
Our findings are consonant with those of other investi-
gators. In a retrospective review of patients after biopros-
thetic AVR, Moinuddeen and associates9 observed no dif-
ference in incidence of stroke risk between 109 patients
receiving heparin followed by 3 months of warfarin, com-
pared with 76 patients receiving no anticoagulation. In their
study, as in ours, the bleeding risk was no higher in the
warfarin group. In a review of patients receiving no antico-
agulation after tissue AVR, Babin-Ebell and colleagues10
observed a stroke rate of only 1.75% in the first 6 months
TABLE 7. Univariable analysis for bleeds within 3 months
Variable* Odds ratio 95% CI P value
Male 2.75 0.59, 12.76 .20
Diag of CAD 0.38 0.12, 1.25 .11
Hypertension 0.34 0.10, 1.5 .08
Prior CVA 1.15 0.15, 9.09 .89
Prior CV intervention 0.66 0.14, 3.09 .60
Prior CABG 0.86 0.11, 6.76 .88
CAB done 0.66 0.20, 2.18 .50
Warfarin 1.49 0.43, 5.11 .53
Age 0.72 0.43, 1.19 .20
CI, Confidence interval; diag, diagnosis; CAD, coronary artery disease;
CVA, cerebrovascular event; CV, cardiovascular; CABG, coronary artery
bypass grafting; CAB, coronary artery bypass. *A stepwise multivariable
logistic model was done with all of the above variables. Age has been
adjusted for 10-year intervals. No variables were significant in the multi-
variable model.among 54 patients. No control group was provided; how-
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early anticoagulation was employed.1 These results are con-
sistent with Turpie’s11 observations that a less-intensive
anticoagulant regimen was equally effective and, in fact,
safer for patients with tissue valves. Most recently, Gherli
and associates12 have conducted a prospective randomized
study of anticoagulation after bioprosthetic AVR. In their
study, there was no difference in cerebral ischemic events
between a group of 141 patients receiving warfarin for 3
months and 108 receiving only aspirin. Again, there was
also no difference in major bleeding events between the
groups.
The results of our current study are at variance with
AHA/ACC and ACCP recommendations, as well as with a
previous report from our own institution.7 This study, pub-
lished by Heras and colleagues,7 provides much of the
support for the guidelines as written. In that study, the
authors identified a significant risk of neurologic events
during the first 3 months after bioprosthetic valve replace-
ment. The overall risk was higher after mitral than AVR and
was particularly high in the first 10 days postoperatively. In
this interval, there were 5 strokes among 424 patients un-
dergoing bioprosthetic AVR, all of which occurred among
patients not receiving anticoagulation. The risk fell precip-
itously thereafter to a linearized rate of 3.6% per year
between 10 and 90 days, and 1.9% per year thereafter. The
authors concluded that early anticoagulation to an interna-
tional normalized ratio of 3.0 to 4.5 may be advisable. They
did not, however, distinguish between prostheses in the
mitral and aortic positions. Curiously, the protective effect
of anticoagulation was only slight after mitral valve replace-
ment and was not seen at all among double valve replace-
ment patients. Furthermore, while approximately one third
of the patients were given anticoagulants postoperatively, in
two thirds of those cases the prothrombin time was less than
1.3 seconds during the high-risk first 10 days when an
apparent protective effect was observed.
The explanation for the differences in outcome between our
current study and the previous report from our own institution
is a matter of speculation. Variations in follow-up are always
a consideration, although information for the earliest post-
operative interval—when the greatest risk of stroke was
identified—should be comparable. Differences in the crite-
ria for stroke could play a role as well, although we at-
tempted to use as inclusive a definition as possible. The
most tempting explanation is that the liberal use of platelet
inhibitors in current clinical practice has reduced these early
events. We support this approach and routinely administer
aspirin after bioprosthetic AVR.
Our current study suffers from significant weaknesses to
be sure. The retrospective design makes “intention to treat”
analysis impossible, complicating the interpretation of data
for the AC and AC– groups. The subtle effects of selec-
The Journal of Thoraciction bias may also impact any nonrandomized study. Prac-
tice patterns during the study interval were relatively con-
sistent within any individual surgeon’s practice, however,
and referral for AVR within our institution is relatively
evenly spread among surgeons. While referral is not ran-
dom, it is certainly not based on anticoagulation philosophy.
Surgeons with larger and smaller total case volumes were
also represented in both groups. Follow-up was incomplete
as well. Unfortunately, because of current government reg-
ulations related to privacy, it is unlikely that more complete
information can be obtained in a retrospective study such as
this.
As in other retrospective analyses, imprecise definition
of the etiology of neurologic events is a difficulty in this
study. Review of the hospital records showed that neuro-
logic consultation was not uniform. The choice of imaging
studies varied, and the assessment of embolic versus non-
embolic etiology was not routinely documented. Subtle
events may have been missed. The attribution of some
events to the intraoperative period carries the potential for
error as well. In contrast to the observations made in the
setting of coronary bypass surgery by Hogue and col-
leagues,13,14 a great many of the cerebrovascular accidents
observed in the current study appeared to be intraoperative.
In their analysis, 65% of perioperative strokes were delayed.
This difference is likely due to the open versus closed nature
of the procedures, the potential for embolization of debris
from the valve annulus, and the lower incidence of gener-
alized atherosclerosis among patients undergoing AVR.
Finally, despite being the largest study in the literature,
our sample size remains far too small to definitively answer
the question posed. The data supporting early anticoagula-
tion are remarkably sparse as well, however. The authors of
the AHA/ACC guidelines reference only the Heras7 paper
in support of early anticoagulation. In their consensus report
for the ACCP, Stein and colleagues4 cited the event rate of
1.8% without anticoagulation reported by Babin-Ebel10 (54
patients), compared with Turpie’s11 report of no events with
heparin and warfarin (109 patients). Although the event
rates differ, the exceedingly small numbers of patients in
both series make conclusions tenuous at best.
The results presented here may be fairly considered a test
of the hypothesis generated by the earlier work from our
institution. On the basis of that work, some surgeons in the
group were stimulated to pursue an aggressive approach to
anticoagulation. The results obtained do not support the
notion that early anticoagulation after bioprosthetic AVR
reduced stroke risk. Conversely, there was no increased risk
of complications. We believe that one can reasonably adopt
a posture of equipoise on the matter. The results of this
study further suggest that efforts to reduce the risk of
cerebral events after AVR might be best directed toward the
intraoperative period. Recently introduced devices intended
and Cardiovascular Surgery ● Volume 129, Number 5 1029
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valve intraoperatively may find particular application in this
regard.
We gratefully acknowledge the assistance of Judy R. Lenoch,
Christina M. Sannes, and Diana L. Lesmeister for their assistance
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Dr John Chen (Honolulu, Hawaii). In this presentation, Dr Sundt
and colleagues challenge the ACC and AHA guidelines for the use
of warfarin therapy after implantation of biologic aortic valves.
The ACC/AHA guideline for valvular heart disease is a 35-page
comprehensive summary published in the Journal of Heart Valve
Disease in 1998. The current guidelines recommend anticoagula-
tion for the first 3 months with a target international normalized
ratio (INR) of 2 to 3. The evidence for support of the guidelines
has been cited as class IC, which signified general agreement that
anticoagulation is useful based on nonrandomized retrospective
studies. The pathologic events leading to thromboembolism are
activated platelets and factor XII. Platelet deposition and factor XII
have been found on Dacron rings, and this is the impetus for their
recommendation. The current AHA guidelines recommend that,
after 3 months, warfarin can be discontinued in more than two
thirds of the patients. The guidelines recommend lifelong antico-
agulation in those with risk factors for thromboembolism, such as
atrial fibrillation, previous thromboembolism, and hypercoagula-
ble conditions. It is important to note that the published guidelines
differentiate between valves in the mitral versus the aortic position,
but the presented study is confined to only biological valve re-
placement in the aortic position.
I applaud the study group for directing our attention to the
guidelines and questioning its validity. I must admit that our
cardiac unit does not believe all patients receiving bioprosthetic
aortic valves should be anticoagulated. Unfortunately, given the
presented findings of an event incidence of 2% to 7% with a 1.2%
difference in stroke and 2% difference in bleeding, this study like
all those previously published is insufficiently powered to answer
the question is early anticoagulation necessary after bioprosthetic
AVR. A clinical trial of more than 40,000 patients would be
required to answer this question. I have the following questions.
Is your nonanticoagulated group sicker than the anticoagulated
group due to the fact that the anticoagulated group had a lower
pump run and a higher operative mortality?
My second question refers to the percentage of anticoagulated
patients receiving heparin prior to oral anticoagulation.
Finally, did your target INR vary depending on the valve brand
used?
Dr Sundt. Thanks very much for those questions.
The first one, are the 2 groups really different, is obviously a
difficult one and that is the Achilles heel in any retrospective study.
You do the best you can looking back in the charts to see if they
are comparable or not. As I said in the presentation, I think that the
reason for the difference in the operative mortality is to some
degree the patients that were particularly ill and died early on
never made it to being anticoagulated. That is, however, only
conjecture. I think the difference in the pump run is frankly a
difference in which surgeons practice which approach. One of the
surgeons who is particularly expeditious in his procedures is one of
the ones who does not anticoagulate patients routinely. Ultimately
I agree it is an almost unanswerable question, are the 2 groups
different? Despite this, I was still struck by how similar the
distribution of events was in the 2 groups.
I respect the criticism that the study cannot be adequately
powered to reverse the current guidelines. I would argue, however,
that it is at least as strong as the studies that support the guidelines.
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CDWe are really left once again with the logical but unproven
argument that we should administer anticoagulants until the sew-
ing ring is endothelialized. I think that I would agree that this paper
cannot answer the question any more rigorously than the other
papers that claim one should anticoagulate.
As for the percentage of patients receiving heparin, I do not
know that. We could go back and look at the charts for that. I can
tell you, however, that this is the routine for the surgeons who do
anticoagulate. This was quite striking to me. I had not seen that
done before. I think the majority of those patients were treated with
heparin early on and we could go back and look at that.
Did the target INR vary by prosthetic device? No, it didn’t. The
target INR was similar regardless of the manufacturer of the
bioprosthetic valve.
Dr Chen. Were the valves studied pretty consistent across your
entire group, that is, was it one particular valve used or multiple
valves used?
Dr Sundt. Multiple valves were used over the course of that
time period, so I suppose that is another potential confounding
variable if there is a difference in thromboembolic risk among the
valves. Perhaps there are differences in how much Dacron is on the
prostheses, so I suppose that is a possibility. I would not have
expected that, but I suppose that’s a possibility.
Dr Vaughn Starnes (Los Angeles, Calif). It is a very timely
topic, and I am glad you brought it to this meeting. We are finding
our valve patients are very much older than they were 5 or 10 years
ago. I think a lot of us have adopted this policy just because of the
aged population we are operating on. Do you have any recommen-
dations in terms: Is there age criteria that you are more prone to do
this protocol versus a younger age patient, for example?
Dr Sundt. I actually do not anticoagulate early, and I think that
this supports that practice. I think as the population ages it is more
supportive of the notion of not anticoagulating people. That’s
really what my practice has been.
The Journal of ThoracicDr Royce Calhoun (Sacramento, Calif). One thing to me that
was just as impressive, as you pointed out, that the complication
rate (ie, bleeding) is no higher, which I think is encouraging, so I
guess one question for you and anyone that may know this, given
that is sort of the official guideline that are often cited and where
I trained we didn’t use routine warfarin as well.
Dr Sundt. You did not.
Dr Calhoun. Did not, no. What is this situation if we do that
and do not use warfarin and then somebody has a stroke and is
litigious? Is that something that we have to worry about defending
against? Do you know that?
Dr Sundt. Presumably, and that was part of the driver for doing
this. It would be difficult to defend, I suppose, and these guidelines
have enormous impact, enormous medicolegal implications. That
is a factor as The Society of Thoracic Surgeons comes out with
their practice guidelines as well. I think that the guidelines can
really drive your practice and it is important to have good data for
those.
Dr Calhoun. What is your protocol for mitral valves?
Dr Sundt. For mitral valves, I do exactly what the guidelines
suggest actually, which is I anticoagulate them with warfarin. I
have not used early heparin. In fact, at Mayo there is a tendency to
use early heparin with mechanical or bioprosthetic valves, and I
was accustomed to waiting until we were 5 days out, and, if we
were not therapeutic, then starting heparin, but a more aggressive
approach is used by some. I was surprised to see no more bleeding
episodes than this.
Dr Chen. I’d like to address the issue of the guidelines.
Because of this paper, I did sit down and read the entire 35 pages
of this thing, and I must say that this is worth reading. The
guidelines do specifically state that these are guidelines. These are
not rules that are meant to be followed. They do allow room for
individual patient treatment, and so I would refer to that, to say that
these are the recommendations, but it is not an absolute rule.
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